ADG126
Our SAFEbody product candidate, ADG126 is a fully human anti-CTLA-4 SAFEbody designed to address the safety concerns associated with existing CTLA-4 therapeutics. It is designed to enhance the safety features by masking the antibody binding site of ADG126, which would be unmasked in the TME, where the activated ADG126 would block CTLA-4 and deplete regulatory T-cells by means of enhanced antibody-dependent cellular cytotoxicity, or ADCC.
ADG126 is in phase 1b/2 development in patients with advanced/metastatic solid tumors, with dose expansion ongoing in combination with anti-PD-1 therapies.